Pheophorbide A–Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD–L1 Expression

Although the immune checkpoint blockade (ICB) has made a great success in cancer immunotherapy, the overall response rate to the ICB, such as anti–programmed death ligand 1 (PD–L1) therapy, remains only at 20–30%. One major reason is the low expression level of the immune checkpoint in a certain typ...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Qinli, Xu, Jiaojiao, Wu, Aihua, Zhang, Chen, Yang, Afeng, Zhang, Sihang, Lin, Hongzheng, Lu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697200/
https://www.ncbi.nlm.nih.gov/pubmed/36432703
http://dx.doi.org/10.3390/pharmaceutics14112513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697200/
https://www.ncbi.nlm.nih.gov/pubmed/36432703
http://dx.doi.org/10.3390/pharmaceutics14112513

Ejemplares similares